ClinicalTrials.gg
Sign In
RecruitingNCT06739759OHSSUpdated Dec 18, 2024

Ovarian Hyperstimulation Syndrome Prevention

An interventional study of Antagonist protocol for IVF and Modified Agonist protocol for IVF with additive treatments as HCQ in Ovarian Hyper Stimulation Syndrome (OHSS), sponsored by Aljazeera Hospital. Recruiting at 2 sites in Egypt. Open to female participants aged 19 Years to 42 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Aljazeera Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
19 Years to 42 Years
Sex
Female
01

Study summary

Ovarian hyperstimulation is a very hazardous complication of ICSI

Read the detailed description

Ovarian hyperstimulation could be mild , moderate , severe or marked

02

Conditions studied

  • Ovarian Hyper Stimulation Syndrome (OHSS)

Keywords

  • OHSS
  • mild
  • Moderate
  • Severe
03

In context

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.

This study's planned enrollment of 300 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Aljazeera Hospital is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with PCOS coming for ICSI

Exclusion criteria

Exclusion Criteria:

  • Women who donnot have PCOS
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    antagonist

    patients with PCOS undergoing ICSI receiving antagonist protocol

    Drug: Antagonist protocol for IVF

  • Active comparator
    Modified agonist with additives

    Patients with PCOS undergoing ICSI receiving modified agonist protocol with additives

    Drug: Modified Agonist protocol for IVF with additive treatments as HCQ

Interventions

  • DrugAntagonist protocol for IVF

    antagonist protocol with triggering by Decapeptyl

    Also known as: Antagonist

  • DrugModified Agonist protocol for IVF with additive treatments as HCQ

    giving additive drugs to agonist protocolas HCQ

    Also known as: modified agonist with additives

06

What researchers measure

Primary outcomes

  1. prevention of OHSS

    prevention of symptoms of ovarian hyperstimulation syndrome as amount of ascites in litres by US

    Time frame: within 3 weeks

07

Study locations

2 of 2 sites recruiting
  • Aljazeerah hospital
    Giza, 12345, Egypt
    Recruiting
  • Algazeerah
    Giza, Egypt
    Recruiting
    • Mahmoud Alalfy, master · Contactmahmoudalalfy@ymail.com · +201002611058
    • Ahmed Elgazzar, M.D · Contact+201014005959
    • Mahmoud Alalfy, master · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.

Of 141 non-industry interventional studies with no phase under Lymphoma, Follicular, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 47. This study's planned 7 months is below that.

Counting every sponsor, half of 165 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Dec 18, 2024
StartActual
Nov 17, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jul 30, 2025
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06739759
Lead sponsor
Aljazeera Hospital
Responsible party
Mahmoud Alalfy (National Research centre, Aljazeera Hospital) — Principal investigator
First posted
Dec 18, 2024
Start date
Nov 17, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Dec 18, 2024

Study contacts

Mahmoud Alalfy, MD
Contact
mahmoudalalfy@ymail.com
01002611058
Ahmed Elgazzar, MD
Contact
elgazzara50@gmail.com
01014005959
Mahmoud Alalfy, MD
study chair · Aljazeera Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antagonist

Other studies in this condition

Lymphoma, Follicular →

Other studies from this sponsor

Aljazeera Hospital

Start the discussion